Evogene
EVGN
18 hedge funds and large institutions have $50.1M invested in Evogene in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 1 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
4% more capital invested
Capital invested by funds: $48.4M → $50.1M (+$1.76M)
0.05% more ownership
Funds ownership: 2.94% → 2.99% (+0.05%)
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$502K |
| 2 |
SWM
Stockman Wealth Management
Billings,
Montana
|
+$250K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$166K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$130K |
| 5 |
Citigroup
New York
|
+$20.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$179K |
| 2 |
Jane Street
New York
|
-$78K |
| 3 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$15.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.93K |
EVGN Hedge Fund Activity: Q3 2016 in Review
18 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2016, worth a combined $50.1M — up 3.6% from $48.4M a quarter earlier.
Fund positioning in EVGN was balanced in Q3 2016: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was UBS Group, adding an estimated $502K. The largest seller was Wellington Management Group, cutting an estimated $179K.
- 18 institutional investors held Evogene (EVGN) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $50.1M of Evogene stock for Q3 2016, up 3.6% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q3 2016 and 1 closed out, a net change of 0 holders.
- The largest Evogene buyer in Q3 2016 was UBS Group, an estimated $502K added.
- The largest Evogene seller in Q3 2016 was Wellington Management Group, an estimated $179K sold.
Based on aggregated 13F filings for Q3 2016.